{
    "organizations": [],
    "uuid": "24c77b4ad036bf8f5e626d392a7a7d1eca25bb87",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merrimack-pharmaceuticals-reports/brief-merrimack-pharmaceuticals-reports-q1-operating-loss-per-share-of-1-33-idUSASC0A0CW",
    "ord_in_thread": 0,
    "title": "BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Merrimack Pharmaceuticals Inc:\n* Q1 OPERATING LOSS PER SHARE $1.33 * THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES\n* MERRIMACK - BELIEVE CASH,CASH EQUIVALENTS OF $76.3 MILLION AS OF MARCH 31&SOME MILESTONE PAYMENTS ANTICIPATED FROM SHIRE TO BE ENOUGH TO FUND INTO H2 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T18:35:00.000+03:00",
    "crawled": "2018-05-09T12:32:16.028+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "merrimack",
        "pharmaceutical",
        "inc",
        "q1",
        "operating",
        "loss",
        "per",
        "share",
        "three",
        "clinical",
        "readout",
        "expected",
        "including",
        "data",
        "two",
        "randomized",
        "phase",
        "study",
        "merrimack",
        "believe",
        "cash",
        "cash",
        "equivalent",
        "million",
        "march",
        "milestone",
        "payment",
        "anticipated",
        "shire",
        "enough",
        "fund",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}